Opening Day: Infinity Natural Resources valued at $1.3B in market debut
Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut
Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...
Max Iron Brazil Ltd Has Received In-Principle Advice on Suitability from the ASX to Advance Plans for Admission to the Official List of the ASX
The Company has added an Australian entity, Max Brazil, to hold the "Florália DSO Project" through the existing Canadian and Brazilian holding entities. As announced on January 9, 2025, Max Brazil ...
Crain's New York3h
FiDi-based obesity drug maker sees $1.9B IPO
Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.
Infinity Natural Resources IPO raises $265m, bringing company valuation to $1.18bn
The company launched the IPO after doubling revenue in 2024, driven by increased oil production from well acquisitions worth ...
Zawya15h
Pearl Energy-backed Infinity Natural Resources raises $265mln in US IPO
Infinity is going public after more than doubling its revenue in the first nine months of 2024. The strong growth came as the ...
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...